特别提示： 上市公司及其控股子公司对外提供的担保总额，超过上市公司最近一期经审计 净资产 50%，请投资者充分关注担保风险。 通化金马药业集团股份有限公司（以下简称"公司"）第十一届董事会 2025 年 第九次临时会议于 2025 年 11 月 12 日召开，会议审议通过了《关于全资子公司为母 公司提供担保额度预计的议案》。具体情况公告如下： 一、担保情况概述 （一）担保事项的基本情况 证券代码：000766 证券简称：通化金马 公告编号：2025-43 通化金马药业集团股份有限公司 关于全资子公司为母公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 因生产经营和业务发展需要，为了保证公司经营有序进行，公司全资子公司成 都永康制药有限公司及哈尔滨圣泰生物制药有限公司拟根据实际情况共同为母公司 融资贷款提供担保额度不超过 35,000 万元。其中：共同为母公司在中国建设银行股 份有限公司通化分行融资贷款提供担保额度不超过 15,000 万元，共同为母公司在吉 林银行股份有限公司通化新华支行融资贷款提供担保额度不超过 20,000 万元。 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-41 通化金马药业集团股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.拟续聘的审计机构名称：北京德皓国际会计师事务所（特殊普通合伙） 2.公司董事会审计委员会、董事会对本次拟续聘会计师事务所事项无异议。 本事项尚需提交公司股东会审议。 3.本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有 企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 通化金马药业集团股份有限公司（以下简称"公司"）于2025年11月12日召 开第十一届董事会2025年第九次临时会议，审议通过了《关于续聘公司2025年度 审计机构的议案》，拟续聘北京德皓国际会计师事务所（特殊普通合伙）（以下简 称"德皓会计师事务所"）担任公司2025年度审计机构，负责公司2025年度财务 审计及内部控制审计等工作。本事项需提交公司2025年第四次临时股东会审议。 现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、机构 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-44 通化金马药业集团股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 28 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2025 年 11 月 28 日 9:15 至 15:00 的任意时间。 1、股东会届次：2025 年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 28 日 14:30 8、会议地点：吉林省通化市二道江区金马路 999 号，公司七楼会议室。 二、会议审 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-40 通化金马药业集团股份有限公司 第十一届董事会 2025 年第九次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第九次临时会议通知 于2025年11月11日以微信和电子邮件形式送达全体董事。 2.2025 年 11 月 12 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 1、审议并通过《关于续聘公司 2025 年度审计机构的议案》 经审议，同意续聘北京德皓国际会计师事务所（特殊普通合伙）担任公司 2025 年度审计机构，负责公司 2025 年度财务审计及内部控制审计等工作。详见同日公司 在巨潮资讯网披露的《关于拟续聘会计师事务所的公告》。 本议案已经董事会审计委员会全票审议通过。 表 ...

11月12日，通化金马涨5.38%，截至发稿，报29.21元/股，成交2.71亿元，换手率0.99%，总市值282.31 亿元。 资料显示，通化金马药业集团股份有限公司位于吉林省通化市二道江区金马路999号，成立日期1993年2 月26日，上市日期1997年4月30日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构成 为：生化药59.27%，中成药40.56%，原料药0.10%，其他0.07%。 从通化金马十大流通股东角度 数据显示，华夏基金旗下1只基金位居通化金马十大流通股东。华夏中证1000ETF（159845）三季度新 进十大流通股东，持有股数525.31万股，占流通股的比例为0.54%。根据测算，今日浮盈赚取约782.71 万元。 华夏中证1000ETF（159845）成立日期2021年3月18日，最新规模454.69亿。今年以来收益27.98%，同 类排名1929/4216；近一年收益15.96%，同类排名2386/3937；成立以来收益28.76%。 华夏中证1000ETF（159845）基金经理为赵宗庭。 截至发稿，赵宗庭累计任职时间8年212天，现任基金资产总规模3558.65亿元，任 ...

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with a year-to-date increase of 76.75%, despite a slight decline in the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while the net profit attributable to shareholders increased by 4.35% to 24.96 million yuan [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 11, 2023, Tonghua Jinma's stock was trading at 27.75 yuan per share, with a market capitalization of 26.82 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 142 million yuan on September 11 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 circulating shares per shareholder, an increase of 3.31% [2][3]. - Notable shareholders include Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings compared to the previous period [3].

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

Core Viewpoint - Tonghua Jinma announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million RMB to support its overall strategic planning and R&D needs [2] Group 1: Company Announcement - The company held the 8th temporary meeting of the 11th board of directors on November 6, 2025, to review the proposal for the establishment of the subsidiary [2] - The investment will be funded through the company's own or self-raised funds [2]

Group 1 - The company announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic planning and R&D needs [1][3] - The company operates in various fields including oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1] - The R&D process is managed by the headquarters, with production bases conducting projects based on their characteristics and market layout, including both innovative and generic drug development [1] Group 2 - The company received a notice of acceptance for the market application of Amber Dihydroaminoacridine Tablets, a new drug for treating mild to moderate Alzheimer's disease, which has undergone extensive clinical trials since 2007 [2] - The company emphasizes that new drug development is a long-term, high-investment, and high-tech process, with uncertainties regarding market prospects and economic returns [2] - The establishment of the subsidiary is part of the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise, enhancing its core competitiveness and ensuring sustainable development [3]

Core Viewpoint - Tonghua Golden Horse plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to enhance its strategic focus on innovation-driven development in the pharmaceutical industry [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary aligns with the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise [1] - The move aims to strengthen the company's capabilities in mergers and acquisitions within the innovative drug sector, thereby enhancing its core competitiveness [1] Group 2: Long-term Sustainability - The initiative is intended to inject new momentum into the company's long-term sustainable development [1]